A Phase 1 interventional study of ASC50 tablets or matching placebo in Plaque Psoriasis, sponsored by Ascletis Pharma (China) Co., Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Ascletis Pharma (China) Co., Limited (part of Ascletis Pharma Inc.) · Phase 1, Interventional, and Treatment
Among 763 studies in Psoriasis with a site in United States — 54 open to participants now, 85 under way, 19 of them phase 3. Psoriasis · United States.
Among the 763 studies in Psoriasis with a site in United States, this one is the 377th largest by enrollment of the 672 interventional ones that give a count, is one of 25 that started in 2025, is one of 85 in phase 1, and was the 735th registered.
2,028 studies on the registry are indexed under Psoriasis; 275 are open to participants now.
Browse Psoriasis studies →54 of the 763 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
University of California, San Francisco · Sites in United States
InventisBio Co., Ltd · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 174 Psoriasis studies recruiting now, 91 (52%) set no upper age limit and 67 (39%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
763 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 98 · Phase 2 217 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 25 started in 2025.
This study's enrollment of 55 is below the median of 75 across 1,565 interventional studies indexed under Psoriasis.
Median enrollment 77 across the 672 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 375 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
523 of 763 have an industry lead sponsor. The 10 most frequent:
Ascletis Pharma (China) Co., Limited is the lead sponsor of 12 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Ascletis Pharma (China) Co., Limited has 1 study filed under Psoriasis — fewer than ten, so there is no comparison to draw.
22 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Among the 763 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, food effect of ASC50 tablets in healthy adult participants and adult participants with mild to moderate plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single ASC50 (Dose 1) administration or matching placebo
Drug: ASC50 tablets or matching placebo
Participants will receive a single ASC50 (Dose 2) administration or matching placebo
Drug: ASC50 tablets or matching placebo
Participants will receive a single ASC50 (Dose 3) administration or matching placebo
Drug: ASC50 tablets or matching placebo
Participants will receive a single ASC50 (Dose 4) administration or matching placebo
Drug: ASC50 tablets or matching placebo
Participants will receive a single ASC50 (Dose 5) administration or matching placebo
Drug: ASC50 tablets or matching placebo
Participants will receive a single ASC50 (Dose 6) administration or matching placebo
Drug: ASC50 tablets or matching placebo
Participants will receive ASC50 (Dose 1) or matching placebo for 28 days, QD
Drug: ASC50 tablets or matching placebo
Drug: ASC50 administered orally Drug: Placebo administered orally
Adverse Events
Evaluate the incidence of Serious Adverse Events (SAEs) and Adverse Events (AEs)
Time frame: Up to Day 7
Adverse Events
Evaluate the incidence of Serious Adverse Events (SAEs) and Adverse Events (AEs)
Time frame: Up to Day 43
AUC
Evaluate the Area under the plasma concentration versus time curve of ASC50
Time frame: Up to Day 7
AUC
Evaluate the Area under the plasma concentration versus time curve of ASC50
Time frame: Up to Day 34
Cmax
Evaluate the Peak Plasma Concentration of ASC50
Time frame: Up to Day 7
Cmax
Evaluate the Peak Plasma Concentration of ASC50
Time frame: Up to Day 34
T1/2
Evaluate the Terminal-Phase Half-Life of ASC50
Time frame: Up to Day 7
T1/2
Evaluate the Terminal-Phase Half-Life of ASC50
Time frame: Up to Day 34
Tmax
Evaluate the time to reach the maximum concentration of ASC50
Time frame: Up to Day 7
Tmax
Evaluate the time to reach the maximum concentration of ASC50
Time frame: Up to Day 34
IL-17A
Changes in IL-17A after ASC50 administration
Time frame: Up to Day 7
IL-17A
Changes in IL-17A after ASC50 administration
Time frame: Up to Day 29
Beta Defensin-2
Changes in Beta Defensin-2 after ASC50 administration
Time frame: Up to Day 29
IL-19
Changes in IL-19 after ASC50 administration
Time frame: Up to Day 29
Psoriasis Area and Severity Index (PASI)
Changes in Psoriasis Area and Severity Index (PASI) after ASC50 treatment.
Time frame: Up to Day 43
Target Lesion Severity Score (TLSS)
Changes in Target Lesion Severity Score (TLSS)after ASC50 treatment.
Time frame: Up to Day 43
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Jul 2026, 12 months.
Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 12 months is above that.
Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jun 2026 → Jul 2026 and completion Jun 2026 → Jul 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ascletis Pharma (China) Co., Limited →